Dr.Doaa Abdel-aziz

Dr.Doaa Abdel-aziz |Clyto Access

Future University in Cairo

Organizing Committee Member

Expertise: Pharmacogenetics, Clinical Pharmacy, Pharmacy Practice, Patient Counseling, Drug Interactions, Clinical Trials And Management Of HCV

Biography: Dr. Doaa Abdel-aziz received a PhD in clinical pharmacy from Cairo University in Egypt and is currently teaching Pharmacotherapy I, II, and pharmacy practice at Future University in Cairo, Egypt. Prior to receiving the PhD degree, she worked as the head of clinical pharmacy department in the National Hepatology and Tropical Medicine Research Institute (NHTMRI) at Cairo, Egypt. She selected, developed and coached a qualified 5 member team and implemented the clinical pharmacy services in NHTMRI.

Presentation:

Title: Effect of HCV and gene polymorphisms on drug toxicities in children

Abstract:

The aim of the present study is to determine the correlation of HCV infection and polymorphisms in different genes with toxicity of either MTX or 6-MP administered to children with ALL methods: A hundred children with low risk ALL who were treated according to the St. Jude Total therapy XV were recruited. The recruited children were receiving MTX and 6-MP during maintenance phase. Patients were excluded from the study if they had other types of leukemia. Genotyping analyses for the TPMT, MTHFR, and GST genes were performed using a combination of PCR and PCR-RFLP protocols. Relevant clinical data on adverse drug reactions were collected objectively (blinded to genotypes) from the patient medical records. Results: There was a significant correlation between the combined presence of HCV and TPMT*3B G460A gene polymorphisms and grade 2-4 AST hepatotoxicity (p < 0.04). The same observation was seen when comparing either the presence of HCV alone or the presence of the gene polymorphism alone. A significant association between the combined presence of HCV and MTHFR C677T polymorphism and grades 2-4 ALT, AST, and ALP hepatotoxicity was observed (p values < 0.001, 0.02 and 0.001 respectively). The presence of HCV infection had a significant negative effect on hepatic transaminases. Conclusions: The present data support a role for combining analysis of genetic variation in drug-metabolizing enzymes and the presence of HCV in the assessment of specific drugs toxicities in multi-agent chemotherapeutic treatment regimens.

Related Conferences :

International Conference on Cancer Care and Cure